Sterling Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Sterling Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180	Buy	+46	New	+$462	﹤0.01%	3264

Other funds holding ELTX

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

MFA

Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Sterling Capital Management's ELTX Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 46 shares worth $180. The stake represents ﹤0.01% of the portfolio and ranks #3264 among its holdings.

11 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Sterling Capital Management held 46 shares of Elicio Therapeutics worth $180 as of Q2 2026.
Elicio Therapeutics was a new Sterling Capital Management position in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3264 holding.
11 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.